FE
Fermenta Biotech Ltd (FERMENTA)
₹572.40
Mkt cap
₹1,395 Cr
P/E ratio
25.50
P/B
4.15
Div yield
0.79%
ROE
16.40%
ROCE
20.60%
EPS (TTM)
₹22.45
Book value
₹138
52W range
249–580
Sector
Healthcare
Price history
Previous close
Incorporated in 1951, Fermenta Biotech Ltd manufactures Active Pharmaceutical Ingredient, Aqua CHL, Biotechnology and Nutraceutical products [1]
NSE FERMENTABSE 506414
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−1.39% from high₹572
₹249+130.02% from low₹580
Current
₹572.40
Prev close
₹555.50
Day
+3.04%
Price performance
1D
+3.04%
1W
+19.42%
1M
+13.96%
3M
+55.29%
6M
—
1Y
—
YTD
+79.77%
Financials
Revenue, profit & margin
P/E ratio
25.5×
FERMENTA is 26% below the sector median of 34.6×
FERMENTA25.5×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 82.45 | 56.91 | 98.97 | 97.34 | 78.13 | 95.03 | 156.47 | 139.85 | 136.26 | 130.22 | 137.36 | 121.58 | 121.82 | |
| Expenses | 71.52 | 70.82 | 73.84 | 91.96 | 77.33 | 76.25 | 103.20 | 102.90 | 108.02 | 103.58 | 112.40 | 101.58 | 103.76 | |
| Operating Profit | 10.93 | -13.91 | 25.13 | 5.38 | 0.80 | 18.78 | 53.27 | 36.95 | 28.24 | 26.64 | 24.96 | 20.00 | 18.06 | |
| OPM % | 13.26% | -24.44% | 25.39% | 5.53% | 1.02% | 19.76% | 34.04% | 26.42% | 20.73% | 20.46% | 18.17% | 16.45% | 14.83% | |
| Other Income | 2.01 | -5.53 | 2.52 | 5.38 | 2.82 | 2.88 | 2.23 | 3.89 | 8.77 | 5.43 | 0.92 | 14.14 | 4.37 | |
| Interest | 4.78 | 3.69 | 5.19 | 3.39 | 3.43 | 3.69 | 4.08 | 2.99 | 3.11 | 2.58 | 3.03 | 2.82 | 2.54 | |
| Depreciation | 5.95 | 5.93 | 6.38 | 6.46 | 6.12 | 6.15 | 6.08 | 5.86 | 5.81 | 5.41 | 5.37 | 5.11 | 5.20 | |
| Profit before tax | 2.21 | -29.06 | 16.08 | 0.91 | -5.93 | 11.82 | 45.34 | 31.99 | 28.09 | 24.08 | 17.48 | 26.21 | 14.69 | |
| Tax % | 0.00% | 0.00% | 37.81% | 884.62% | 0.00% | 5.92% | 16.43% | -4.19% | 23.07% | 25.17% | 31.24% | 29.03% | 35.13% | |
| Net Profit | 2.21 | -29.07 | 9.99 | -7.14 | -5.93 | 11.12 | 37.89 | 33.32 | 21.60 | 18.03 | 12.02 | 18.60 | 9.53 | |
| EPS in Rs | 0.62 | -9.70 | 3.35 | -2.36 | -1.98 | 3.87 | 12.54 | 11.68 | 7.42 | 6.14 | 4.31 | 6.52 | 3.31 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −2.11% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 11 Aug '26 |
| Earnings day | −2.11% |
| +1 day | −4.92% |
| +5 days | −5.74% |
| +15 days | +7.61% |
| +30 days | −1.20% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Aug 202664.09%Promoter
Promoters64.09%0.01
FIIs0.37%0.24
DIIs0.04%
Public32.95%0.24
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Fermenta Biotec. | ₹474.15 | 25.49 | 1,395 | 0.79% | 10 | −55.38% | 122 | −10.60% | 20.57% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Concall transcripts64
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 17 SepAnnouncement under Regulation 30 (LODR)-Newspaper Publication 16 Sep - Copy of Newspaper Publication regarding notice to equity shareholders for transfer of shares to IEPF.Dispatch Of Letters To Shareholders Regarding Transfer Of Equity Shares Of The Company To The Investor Education And Protection Fund ('IEPF') Account. 16 Sep - Fermenta Biotech notifies shareholders to claim unclaimed 2019-20 interim dividend by 18 Nov 2026 before IEPF transfer.Press Release Regarding Exclusive Licence Agreement With Vellore Institute Of Technology ('VIT'), Vellore For Vitamin B12 Fortification Technology. 8 Sep - Fermenta signed exclusive licence with VIT Vellore for Vitamin B12 fortification technology on 8 September 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 27 Aug - Fermenta Biotech to hold one-to-one investor meetings in Mumbai on September 3, 2026.